Isofol secures license rights for arfolitixorin in autism
GOTHENBURG, Sweden, March 18, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded […]
MAR
Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin
GOTHENBURG, Sweden, February 24, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company’s
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million
GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or
Isofol receives regulatory approval to initiate clinical study of arfolitixorin
GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in
Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin
GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary
Isofol announces new preclinical data supporting the previously communicated clinical development plan for arfolitixorin
GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies
Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development
GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that an external committee of
Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin
GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company has signed
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration
Isofol presents a clinical development plan for arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy